Ind-Swift Labs lifts margin as revenue growth outpaces costs
Consolidated revenue rose 25.60% sequentially, but other income contributed 16.32% of pre-tax profit and interest expense jumped 87.32%.
Filed 29 Oct 2026, 14:59 IST · Ind-Swift Laboratories Ltd (INDSWFTLAB)
Key takeaways
- Consolidated revenue grew 25.60% sequentially, while expenses grew 23.40%, lifting operating margin by 1.45 percentage points.
- Net profit rose 38.65% sequentially to Rs 34.22 cr, helped by a 3.22-percentage-point drop in the tax rate.
- The stock rose 9.78% on the results date, while the 18.91% operating margin remained 0.99 percentage points below the Healthcare peer median.
Price around the results
Revenue growth outpaced cost growth in Q2FY27
Ind-Swift Laboratories reported consolidated revenue growth of 25.60% sequentially, ahead of the 23.40% increase in expenses. That operating leverage lifted the margin by 1.45 percentage points to 18.91%, with operating profit rising 35.99%. There is no year-on-year comparison in the reported data.
Lower tax rate supported the profit increase
Net profit increased 38.65% sequentially, faster than pre-tax profit growth of 32.96%. The tax rate fell by 3.22 percentage points to 21.24%, which supported the increase in net profit. Other income accounted for 16.32% of pre-tax profit, so reported earnings included a meaningful non-operating contribution, while interest expense rose 87.32%.
Margin remained below the Healthcare peer median
The 18.91% operating margin was 0.99 percentage points below the 19.90% median for the 31 Healthcare peers that had reported the same quarter. The available quarterly trend shows an improvement from Q1FY27's 17.46%, rather than a continuing decline.
Shares rose sharply on the results date
The stock gained 9.78% on 29 October, the results date, with a 0.54% opening gap and volume at 7.31 times the reference level. The available reaction data does not provide a history of post-results moves, so this response cannot be compared with the stock's usual reaction.
Q2FY27 at a glance
Consolidated figures as filed with NSE — filed ahead of third-party databases, not yet independently cross-checked.
| Line item | Q2FY27 | Q1FY27 | QoQ |
|---|---|---|---|
| Revenue | ₹240 cr | ₹191 cr | +25.60% |
| Other income | ₹7 cr | ₹8 cr | -5.84% |
| Expenses | ₹195 cr | ₹158 cr | +23.40% |
| Operating profit | ₹45 cr | ₹33 cr | +35.99% |
| Operating margin (%) | 18.91% | 17.46% | — |
| Interest | ₹1 cr | ₹1 cr | +87.32% |
| Depreciation | ₹8 cr | ₹8 cr | +2.51% |
| Profit before tax | ₹43 cr | ₹33 cr | +32.96% |
| Tax | ₹9 cr | ₹8 cr | +15.52% |
| Net profit | ₹34 cr | ₹25 cr | +38.65% |
| EPS (₹) | ₹3.94 | ₹2.84 | +38.73% |
Operating margin of 18.91% compares with a Healthcare sector median of 19.90% across 31 peers that have reported Q2FY27.
How the stock reacted
| Window | Stock | vs NIFTY |
|---|---|---|
| Results day | +9.78% | +8.73% |
Volume on the results session was 7.31× its 20-day average.
What to watch
- Whether operating margin holds above 18.91% after the sequential improvement.
- Whether other income remains below or above its 16.32% share of pre-tax profit.
- Whether interest expense continues to grow from its 87.32% sequential increase.